Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study

The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma LTRN to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with chemotherapy for never smoker patients with advanced non-small cell lung cancer (NSCLC).

The Harmonic study is a phase 2 clinical trial investigating the effect of investigational new drug LP-300 in combination with standard of care (SOC) chemotherapy, pemetrexed and carboplatin, on the overall and progression-free survival of never smoker patients with advanced NSCLC.

The Phase 2 study has been designed as a 90 patient trial with approximately two third of the patients receiving LP-300 with chemotherapy and the remaining one third receiving chemotherapy alone.

The company is planning to begin the patient enrolment in the third quarter of 2022.

Panna Sharma, CEO, commented : “LP-300 is an innovative therapy that is being developed for never smokers with NSCLC, a unique and growing population of lung cancer patients whose cancer is genetically different from smokers with lung cancer. LP-300 will be delivered in combination with standard of care chemotherapy. Importantly, LP-300 has been well tolerated in prior clinical trials and has shown potential to protect against harmful effects of chemotherapy while also de-naturing many of the tyrosine kinase receptors through cysteine modification that are involved with NSCLC.”

Price Action : Lantern Pharma Shares are trading around 2 percent higher at $5.97 on Thursday’s pre-market session.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralFDA Clearance
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!